GlycA: A Key Biomarker for Chronic Inflammation and Cardiometabolic Risk
GlycA is an advanced inflammatory biomarker derived from nuclear magnetic resonance (NMR) spectroscopy. Unlike high-sensitivity C-reactive protein (hs-CRP), which indicates acute inflammation, GlycA reflects chronic, persistent inflammation stemming from glycosylated proteins of the innate immune system. Research indicates that GlycA is a strong predictor of cardiometabolic diseases, type 2 diabetes, atherosclerotic cardiovascular disease (ASCVD) events, hospitalization risks, and overall mortality, establishing it as one of the most clinically valuable long-term inflammation markers available today. Precision Health Reports integrates GlycA into comprehensive risk assessments, as it provides a more reliable view of metabolic and vascular inflammation, particularly in patients with metabolic syndrome, obesity, insulin resistance, or chronic fatigue-like syndromes.
GlycA, or glycoprotein acetylation, is a composite biomarker derived from the NMR signal of various acute-phase glycoproteins, including α1-acid glycoprotein, haptoglobin, α1-antitrypsin, transferrin, and α1-antichymotrypsin. These proteins typically circulate at stable baseline levels but increase in response to chronic inflammatory signaling. GlycA is particularly noteworthy for its stability compared to hs-CRP, as it exhibits less biological variability day-to-day and is not influenced by short-term infections, making it a more reliable indicator of chronic inflammation.
Elevated levels of GlycA are associated with a higher likelihood of developing type 2 diabetes, systemic metabolic dysfunction, insulin resistance, and chronic inflammatory conditions such as long-COVID and autoimmune diseases. This biomarker is crucial for understanding the long-term inflammatory burden and its implications for cardiometabolic health, especially when traditional markers may not provide a complete picture.
Despite its potential, GlycA has not yet been standardized as a routine inflammation measure by major U.S. guidelines, such as those from the American College of Cardiology (ACC) or the American Diabetes Association (ADA). Nonetheless, peer-reviewed research consistently supports its value in assessing chronic inflammatory burden and predicting long-term disease outcomes. Organizations like Cleveland HeartLab and LabCorp have already included GlycA in their inflammation panels, highlighting its growing acceptance in clinical practice.
Clinicians are increasingly utilizing GlycA as a risk-enhancing factor in discussions about ASCVD risk, as a marker for metabolic inflammation to identify cardiometabolic dysfunction, and as a monitoring tool during lifestyle or pharmacologic interventions, such as GLP-1s, anti-inflammatories, and weight loss strategies. As research continues to evolve, GlycA is becoming a go-to tool for understanding chronic inflammatory load and its impact on health.
GlycA is measured using NMR spectroscopy, which quantifies the concentration and glycosylation patterns of circulating glycoproteins, with results typically reported in micromoles per liter (µmol/L). Higher levels of GlycA, particularly those exceeding 400 µmol/L, indicate a high risk for cardiometabolic disease and chronic inflammation. Importantly, GlycA levels can respond positively to weight loss, improved fitness, and anti-inflammatory interventions, making it a valuable marker for assessing the effectiveness of lifestyle changes and treatments.
While research supports GlycA as a useful marker for persistent inflammatory load, particularly in post-viral syndromes, definitive conclusions are still pending. It is important to note that GlycA is a specialty test offered by limited laboratories, and its inclusion in risk assessments by entities like Precision Health Reports underscores its relevance in modern healthcare.




